GlassScriptPhysician profile
Roza Vaksengiser
NPI 1881993400
$2,493.09
in general payments reported to CMS, 2019-2025
21 companies · $765 in 2025
The $765 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $586 · 2024: $1,142 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.12 |
| Education | $369.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $526.63 | 2023-2025 | Injectafer, Enhertu, Vanflyta |
| Janssen Biotech, INC. | $326.02 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Beigene USA, INC. | $300.00 | 2023-2024 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $199.90 | 2024-2025 | Monoferric |
| Coherus Oncology, INC. | $147.65 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $145.38 | 2023 | Reblozyl |
| Abbvie INC. | $129.07 | 2024-2025 | |
| Sobi, INC | $125.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $120.50 | 2024 | Enhertu |
| Seagen INC. | $99.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $67.57 | 2025 | |
| Celgene Corporation | $54.20 | 2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $52.77 | 2024 | Keytruda |
| Astellas Pharma US INC | $46.45 | 2025 | Vyloy |
| Acrotech Biopharma INC. | $28.14 | 2025 | Beleodaq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $27.25 | 2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $26.83 | 2024 | Vpriv |
| Celltrion USA INC. | $19.94 | 2025 | Vegzelma |
| Geron Corporation | $19.32 | 2025 | Rytelo |
| G1 Therapeutics, INC. | $15.39 | 2023 | Cosela |
| Genentech USA, INC. | $15.09 | 2025 | Polivy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roza Vaksengiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.